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The incidence of malignant melanoma appears to be increasing at an alarming rate throughout the world over the past 30–40 years
and continues to increase in the United States, Canada, Australia, Asia, and Europe. The behavior of head and neck melanoma is
aggressive, and it has an overall poorer prognosis than that of other skin sites. The authors review the published literature and text
books, intending to give an overall picture of malignant melanomas of the head and neck and a special emphasis on treatment
considerations with controversies in treatment including biopsy, radiation therapy, sentinel node biopsy, and nodal dissection.
1.Background
Melanoma is a malignancy of pigment-producing cells (mel-
anocytes) located predominantly in the skin but also found
intheeyes,ears,GItract,leptomeninges,andoralandgenital
mucous membranes. The incidence of malignant melanoma
appears to be increasing at an alarming rate throughout the
world over the past 30–40 years and continues to increase in
the United States, Canada, Australia, Asia, and Europe [1–3].
Melanoma accounts for 65% of all deaths from skin cancer,
reﬂecting its lethal nature.
Most head andneck melanomas (70–90%) occur on the
face[4],withthecheekthemostcommonsite[5].Malignant
melanomas of the neck (7%) and scalp (3%) are much less
frequent [6, 7]. Melanomas of the external ear constitute 7%
of the head and neck melanomas [8]. Although malignant
melanomas of all cutaneous sites are slightly more common
in women, melanomas of the head and neck are twice as
c o m m o ni nm e n[ 7, 9]. Head and neck melanoma also tends
to aﬀect a slightly older aged group than melanomas in other
sites [10] .H e a da n dn e c km e l a n o m ai nc h i l d r e ni sav e ryra r e
and is usually associated with giant congenital nevus [11].
Melanoma that does not originate in the skin is a very
rare tumor and is considered as one of the most deadly of
all human neoplasms [12, 13]. Primary mucosal melanomas
represent only 1.7–3% of all primary melanomas [1, 14].
Generally, survival from head and neck melanoma is
reported as 17% at 5 years and the 10-year survival rate is 5%
[15].Wehavereviewedthepublishedreportsandtext-books,
intending to give an overall picture of malignant melanomas
of the head and neck.
2.Pathophysiology
The sequence of events in which normal melanocytes trans-
form into melanoma cells, referred to as melanoma genesis,
is poorly understood. It likely involves a multistep process of
progressive genetic mutations that (1) alter cell proliferation,
diﬀerentiation, and death and (2) impact susceptibility to
the carcinogenic eﬀects of ultraviolet radiation [16]. Recent
data suggest multiple pathways of melanoma pathogenesis,
with melanomas in sun-protected skin (trunk) developing
in association with a high nevus count and intermittent
ultraviolet radiation as opposed to those developing on sun-
exposed skin in patients with low nevus counts and chronic
sun exposure [17, 18].
In a recent meta-analysis, Gandini et al, [19]f o u n da
possible positive correlation between an individual’s number
of nevi and the overall risk of melanoma. Other risk factors
include fair complexion, excessive childhood sun exposure
and blistering childhood sunburns, an increased number of
commonanddysplasticmoles,afamilyhistoryofmelanoma,2 ISRN Surgery
Table 1: Characteristics and incidence of morphologic subtypes of melanoma.
Subtype Incidence Special features
Superﬁcial spreading 75% Flat during early phase, typically from preexisting nevus
Nodular 15% Early vertical growth
Lentigo maligna 10% Prolonged radial growth
Acral lentiginous 2–8% Palms, soles, and nail beds
Desmoplastic low Associated with perineural invasion
Mucosal 2% Poorer prognosis
the presence of a changing mole or evolving lesion on the
skin, and, importantly, older age [20, 21].
Finally, genetics may play a role. Patients having at least
one aﬀected ﬁrst-degree relative possess a higher likelihood
ofdevelopingmalignantmelanoma.TheCDKN2A(p16)ch-
romosomal mutation is the most commonly isolated genetic
culprit [22].
3.Diagnosis
A new or changing mole or blemish is the most common
warning sign for melanoma. Variation in color and/or an
increase in diameter, height, or asymmetry of borders of a
pigmented lesion are noted by more than 80% of patients
with melanoma at the time of diagnosis. Symptoms such as
bleeding, itching, ulceration, and pain in a pigmented lesion
are less common but warrant an evaluation.
The American Cancer Society developed the ABCDEs to
serve as a simple guideline of early melanoma warning signs.
(i) Asymmetry: half the lesion does not match the other
half.
(ii) Border irregularity: the edges are ragged, notched, or
blurred.
(iii) Color variegation: pigmentation is not uniform and
may display shades of tan, brown, or black; white,
reddish, or blue discoloration is of particular con-
cern.
(iv) Diameter: a diameter greater than 6mm is a charac-
teristic, although some melanomas may have smaller
diameters; any growth in a nevus warrants an evalu-
ation.
(v) Evolving: changes in the lesion over time are a chara-
cteristic; this factor is critical for nodular or amelan-
otic (nonpigmented) melanoma, which may not ex-
hibit the classic criteria above [23].
More recent use of the “ugly duckling” warning sign,
wherein skin examination is focused on recognition of a pig-
mented or clinically amelanotic lesion that simply looks dif-
ferent from the rest, may assist with detection of lesions that
lack the classic ABCDE criteria (e.g., nodular, amelanotic, or
desmoplastic melanomas) [24].
Experienced visual inspection is often the key to disting-
uishing a melanoma from other common benign pigmented
skin lesions, such as lentigo simplex, junctional nevus, com-
pound nevus, intradermal nevus, blue nevus, amalgam tat-
too, Addison’s disease, and heavy metal poisoning [22].
4. Typesof Melanoma
The appearance and growth of melanoma diﬀer depending
on the morphologic type. Table 1 shows the incidence and
features of six types of melanoma [25].
Superﬁcial spreading melanomas are the most common
type.Theyaretypiﬁedbyaninitialradial(spreading)growth
phase with eventual development of a vertical growth phase.
Superﬁcialspreadingmelanomaisfrequentlyassociatedwith
a nevus and often occurs in younger patients.
Nodular melanomas are the next most common type.
These exhibit vertical growth from their onset.
Lentigo maligna melanomas are characterized by a
prolonged radial growth phase. They tend to start as a slow
growing, ﬂat patch in sun-exposed areas (often the face
and neck). They have a proclivity for the dermal-epidermal
j u n c t i o na n dt e n dt of o l l o wh a i rf o l l i c l e s .
Acral lentiginous melanomas are characteristically locat-
ed on the palms or soles. Not all such lesions are acral lentig-
inous; however, they have a deﬁned histologic appearance.
Desmoplastic melanomas can be seen in association with
preexisting melanocytic lesions and can more frequently be
amelanotic, making their diagnosis more diﬃcult. They tend
to be characterized by infrequent metastasis with a higher lo-
cal recurrence rate, as well as more frequent perineural invo-
lvement.
Mucosal melanomas most frequently present in the nose
and/or sinuses, followed by the oral cavity and nasopharynx.
They are rare lesions but have a poor prognosis. Because of
their development in hidden, clinically silent areas, diagnosis
often occurs late, requiring more radical treatment and cont-
ributing to the poorer prognosis [5].
5. LaboratoryStudies
Themostimportantaspectsoftheinitialworkupforpatients
with melanoma are a careful history, review of systems, and
physical examination.
(i) Sentinellymphnodebiopsy(SLNB)isgenerallyindi-
cated for pathologic staging of the regional nodal
basin(s) for primary tumors greater than or equal to
1mmdepthandwhencertainadversehistologicfeat-
ures (e.g., ulceration, high mitotic rate, and lympho-
vascular invasion) are present in thinner melanomas.ISRN Surgery 3
(ii) Published data have shown that baseline and surveil-
lance laboratory studies (e.g., lactate dehydrogenase
[LDH] level, liver function tests), chest radiography
(CXR), and other imaging studies (e.g., CT scanning,
positronemissiontomography[PET]scanning,bone
scanning, and MRI) are not typically beneﬁcial for
stage I/II (cutaneous) melanoma patients without
signs or symptoms of metastasis [26–28].
(iii) A metastatic workup should be initiated if physical
ﬁndings or symptoms suggest disease recurrence.
ScreeningCTorPETmaybeconsideredifthepatient
has documented nodal metastasis based on results
from the SLNB, although the yield is low (0.5–3.7%)
in the setting of regional nodal micrometastasis and
correlates with increasing tumor thickness, ulcera-
tion of the primary tumor, and/or large tumor bur-
den in the sentinel lymph node(s) [29].
5.1. Procedures. The criterion standard for melanoma diag-
nosis is histopathologic examination of clinically suggestive
skin or mucosal lesions. An excisional biopsy (or deep
saucerization technique) with narrow margins is preferred
when possible. In the case of lentigo maligna, a broad, paper-
thinshavebiopsyormultiplesmallerbiopsiesmaybethebest
techniques. The biopsy report should generally include the
following:
(i) tumor thickness (Breslow depth);
(ii) presence of ulceration;
(iii) anatomiclevelofinvasion(Clarklevel),nolongerne-
cessary as per 2010 AJCC staging [30];
(iv) presenceofmitoses,notedas0or1ormorepermilli-
meter squared;
(v) presence of regression (associated with lower rates
of sentinel node positivity and improved disease-free
survival) [31];
(vi) lymphatic/vessel (lymphovascular) invasion or vas-
cular involvement;
(vii) host response (tumor-inﬁltrating lymphocytes).
Immunohistochemical staining for lineage (S-100, hom-
atropine methylbromide 45 [HMB-45], melan-A/Mart-1)
or proliferation markers (proliferating cell nuclear antigen,
Ki67) may be helpful in some cases for histologic diﬀerentia-
tion from melanoma simulators [5].
5.2. Histological Findings. Malignant cells often nest or clus-
ter in groups in an organoid fashion; however, single cell can
predominate. The melanoma cells have large nuclei, often
with prominent nucleoli and show nuclear pseudoinclusions
due to nuclear membrane irregularity. The abundant cyto-
plasmmaybeuniformlyeosinophilicoropticallyclear.Occa-
sionalzly, the cells become spindled or neurotized in areas.
This ﬁnding is interpreted as a more aggressive feature, com-
pared with the ﬁndings of round or polygonal cell varieties
[22].
5.3. Staging. In 2009, the American Joint Committee on
Cancer (AJCC) Melanoma Task Force (Table 2) revised the
staging system for cutaneous melanomas based upon the
results of their multi-institutional study of 17,600 patients
[32, 33]. Staging adheres to the traditional tumor-node-
metastasis(TNM)classiﬁcationsystem.Thissystemclassiﬁes
melanomas on the basis of their local, regional, and distant
characteristics, as follows:
(i) stage I and II: localized primary melanoma
(ii) stage III: metastasis to single regional lymph node
basin (with or without in-transit metastases)
(iii) stage IV: distant metastatic disease [34].
Estimated 5-year overall survival (OS) in the staging
Table is based on analysis of worldwide data encompassing
nearly 60,000 patients in the 2008 AJCC Melanoma Staging
Database [35].
5.4. Clark Levels. Two popular microstaging systems for me-
lanomaaretheClarklevelsandtheBreslowthicknessclassiﬁ-
cation.Inthepast,Breslowdepthofinvasionhasbeenshown
to have prognostic signiﬁcance, as has Clark level of inva-
sion.Inthenewsystem,Breslowdepthplaysamorevitalrole,
while Clark level is deemphasized (relevant only for T1 lesi-
ons).
Other changes include the presence or absence of tumor
ulceration, as well as tumor (T) thickness limits at 1.0-mm,
2.0-mm, and 4.0-mm depth for deﬁning T stage. Stages I and
II were conﬁned to clinical staging, while stages III and IV
used pathologic information from the nodes to deﬁne stag-
ing. Where the 1997 system used the size of nodal metastases
to judge prognosis, new data have shown that the number of
metastatic nodes is more relevant. The new system reﬂects
that relevance by basing the N (nodal) stage on num-
ber of nodes involved like single or 2-3 or ≥4 metastatic
nodes. In-transit metastases, which were grouped with the
T staging in the 1997 system, are now included with the N
staging. In general, in-transit metastases have been recog-
nized to portend a poorer prognosis, which is reﬂected in the
new system. Distant metastases are now grouped into one of
three groups: M1a (including subcutaneous nodules/distant
nodes), M1b (conﬁned to lung metastases), and M1c (for all
other visceral sites). Elevated lactate dehydrogenase (LDH)
serum level also is associated with poor prognosis, and pa-
tients with distant metastases and increased LDH are stage
M1c regardless of site of metastasis [25].
5.5.EvaluationandTreatment. Suspiciouslesionsaredeﬁned
by the ABCD(E) criteria and the last criterion, which is a
relatively recent addition, emphasizing monitoring of benign
lesions to evaluate change over time [23]. For suspicious
lesions, a full thickness biopsy is crucial for adequate diagno-
sis of lesion depth and invasion.
5.6.Biopsy. Theprognosisandtreatmentofcutaneousmela-
nomadependgreatlyonthethicknessofthelesion.Thus,the
key to evaluation of suspected lesions focuses on obtaining4 ISRN Surgery
Table 2: AJCC 2009 revised melanoma staging.
Stage TNM staging Stage Pathologic staging Histologic/clinical features
Stage 0 Tis N0 M0 0 Tis N0 M0 Melanoma in situ
Stage IA T1a N0 M0 IA T1a N0 M0 Melanomas ≤ 1mm without ulceration and mitosis <
1/mm2
Stage IB T1b N0 M0
IB
T1b N0 M0 Melanomas ≤ 1mm with ulceration or mitosis ≥ 1/mm2
T2a N0 M0 T2a N0 M0 Melanomas 1.01–2mm without ulceration
Stage IIA T2b N0 M0
IIA
T2b N0 M0 Melanomas 1.01–2mm with ulceration
T3a N0 M0 T3a N0 M0 Melanomas 2.01–4mm without ulceration
Stage IIB T3b N0 M0
IIB
T3b N0 M0 Melanomas 2.01–4mm with ulceration
T4a N0 M0 T4a N0 M0 Melanomas 4mm without ulceration
Stage IIC T4b N0 M0 IIC T4b N0 M0 Melanomas 4mm with ulceration
Stage III Any T ≥ N1 M0
IIIA
T1-4a N1a M0 Single regional nodal micrometastasis, nonulcerated
primary
T1-4a N2a M0 2-3 regional nodal micrometastasis, nonulcerated
primary
IIIB
T1-4b N1a M0 Single regional nodal micrometastasis, ulcerated primary
T1-4b N2a M0 2-3 regional nodal micrometastasis, nonulcerated
primary
T1-4a N1b M0 Single regional nodal macrometastasis, nonulcerated
primary
T1-4a N2b M0 2-3 macroscopic regional nodes, no ulceration of
primary
T1–4a N2c M0 2-3 nodes, in-transit met(s)∗ and/or satellite lesion(s)
without metastatic lymph nodes
IIIC
T1-4b N1b M0 Single regional nodal macrometastasis, ulceration of
primary
T1-4b N2b M0 2-3 macroscopic regional nodes, ulceration of primary
T1-4b N2c M0 2-3 nodes, in-transit met(s)∗ and/or satellite lesion(s)
without metastatic lymph nodes, ulceration of primary
Any T N3 M0 4 or more metastatic nodes, or matted nodes, or
in-transit met(s)/satellite (s) with metastatic nodes (s)
Stage IV Any T Any N M1 IV Any T Any N M1
Distant metastasis
M1a: distant skin, subcutaneous, or nodal mets with
normal LDH levels
M1b: lung mets with normal LDH levels
M1c: all other visceral metastases with normal LDH
levels
Distant metastasis with elevated LDH levels
a full-thickness biopsy. Excisional biopsy is the best choice
for small lesions or for large lesions in cosmetically favorable
locations. Excisional biopsy should extend down to the
subcutaneous fat, with a small (2-3mm) peripheral margin.
Punch biopsy can be performed for large lesions or for
lesions with a low suspicion of melanoma in a cosmetically
unfavorable location. The biopsy should be performed at the
highest or thickest point of the lesion.
Incisional biopsy is not recommended. Likewise, tech-
niques that do not permit a full-thickness sample, such
as shave or curette biopsy, are discouraged. Furthermore,
pigmented lesions should not be deﬁnitively treated with
laser therapy, electrocautery, or cryotherapy unless biopsy
analysis proves them to be noncancerous [36].
Some controversy exists in a number of areas. In terms
of excision of the primary site, thin melanoma margins are
generally accepted to be 1cm. For melanomas greater than
2mm in thickness, 2cm margins are the norm. However,
Krown and Chapman [37] noted that the ideal margin width
for these deeper lesions has not been adequately studied.
More information regarding current excision margin recom-
mendations is reviewed on the subject by Lens [38]. In the
headandneckregions,adequatemarginsmaynotbepossible
or advisable due to cosmetic or functional concerns.ISRN Surgery 5
Radiation therapy also has been controversial in the past
due to the fact that the radiosensitivity of melanoma was
at least considered questionable. This is changing as more
recent data becomes available. Adjuvant radiation therapy
for neck disease has been shown to be beneﬁcial for patients
with aggressive disease [39]. There are also data that support
radiation treatment alone for regional disease control in
head and neck melanoma, although no direct comparison of
radiation versus surgical treatment has been studied [40].
5.7. Elective Dissection of the Lymph Nodes. For most solid
tumors, including cutaneous malignant melanoma, the most
powerful predictor of survival is the status of the regional
lymph nodes. As the understanding of the tumor biology of
malignantmelanomacontinuestoevolve,thetraditionalrole
for lymphadenectomy in the evaluation of at-risk regional
nodes has been challenged.
But according to some studies, using this technique
adequate disease removal (e.g., clinically negative neck,
nonﬁxed disease, and small nodes) is possible [41]. Radical
neck dissections, unless indicated because of disease extent,
should be avoided due to unnecessary morbidity. Because of
thehighriskofoccultinvolvednodes,neckdissectionshould
accompany parotidectomy for positive parotid disease [42].
The site of the primary lesion must be considered
when neck dissection is planned in order to remove all
intervening lymphatic drainage to the suspicious or positive
node. The primary site must also be considered when one
plans elective lymph node dissection (ELND) for clinically
negative necks. For primary lesions involving the parietal
or frontal scalp, temple, lateral forehead, lateral cheek, or
ear, superﬁcial parotidectomy in conjunction with neck
dissection is appropriate because the parotid may harbor the
primary echelon nodes [36].
The debate on neck dissection continues as therapeutic
nodal dissection has not been deﬁnitively shown to have
a survival beneﬁt; it improves locoregional control [43].
Adding further complexity to this debate, data show that
recurrence rates in the neck after neck dissection are higher
than those in the axillary or inguinal areas [44].
Thus,untilrecently,astrongargumentcouldbemadefor
the “wait-and-see approach” to the clinically negative nodal
basin because of the morbidity of dissection without evide-
nce of a clear survival beneﬁt. But recent study has shown
that high-dose interferon (IFN) alfa-2b can be given as an
adjuvant treatment for high-risk melanomas and indicated
that elective nodal dissection should not be delayed until dis-
easeisclinicallydetectable.Inthisstudy,relapse-freesurvival
and overall survival rates improved in patients treated with
IFN alfa-2b versus controls subject [45].
5.8. Sentinel Lymph Node Biopsy in the Head and Neck. The
widespread use of sentinel lymph node (SLN) biopsy in
the management of head and neck melanoma has been
limited by several concerns. One is that the lymphatic drai-
nage in the head and neck region is complex, with multiple
primary channels and the potential for multiple SLN sites.
Secondarily excision of these nodes can be technically chal-
lenging as small distances between sentinel nodes make
detectionandisolationdiﬃcult.Furthermore,approximately
25–30% of the sentinel nodes is found within the parotid
gland, and concern of facial nerve injury has led many sur-
geonstoadvocatesuperﬁcialparotidectomyoverSLNbiopsy.
And lastly, the cooperation of experienced pathologists and
nuclear medicine staﬀ are essential to the success of the pro-
cedure [36].
SLNs were successfully localized in greater than 90%
of cases, with the combined use of blue dye mapping and
gamma probe lymphoscintigraphy. 5 studies demonstrated
success rates of 95% or better. The rate of tumor-containing
SLNsrangedfrom11–17%. Additionally,reviewsbySchmal-
bach et al. and Loree et al. describe accurately localizing
intraparotid SLNs in at least 93% of cases [46, 47].
5.9. Medical Care. Numerous adjuvant therapies have
been investigated for the treatment of localized cutaneous
melanoma following complete surgical removal. No survival
beneﬁt has been demonstrated for adjuvant chemotherapy,
nonspeciﬁc (passive) immunotherapy, radiation therapy,
retinoid therapy, vitamin therapy, or biologic therapy [48].
Adjuvant interferon (IFN), alfa-2b, is the only adjuvant
therapy approved by the US Food and Drug Administration
for high-risk melanoma (currently deﬁned as stages IIB,
IIC, and III), which is associated with a 40–80% chance of
relapse and death. Various experimental melanoma vaccines
also show promise in the adjuvant setting [49]. Monoclonal
antibodies are also considered as a second-line treatment for
unresectable or metastatic melanoma.
5.10. Prognostic Factors. The most important prognostic
factors for cutaneous melanoma of the head and neck are as
follows: increasing clark level of invasion, increasing tumor
thickness, site that is scalp, greater than 1 mitosis per high
power ﬁeld, clinical ulceration, component of epitheloid
cells, especially with pleomorphism, presence of microscopic
satellites, lack of tumor inﬁltrating lymphocytes, and regi-
onal lymph node metastasis [5].
6. Conclusions
The incidence of melanoma of the head and neck has been
increasing dramatically in the last several decades. Much of
this change is related to increased sun exposure in the gene-
ral population. Head and neck melanoma is a complex dis-
ease especially in its treatment considerations. Thus a more
aggressive treatment is done when morbidity is not signiﬁ-
cantly increased. As in any other cancer, best opportunity for
cure lies in early and aggressive treatment.
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